{"id":45648,"date":"2025-12-01T11:35:07","date_gmt":"2025-12-01T11:35:07","guid":{"rendered":"https:\/\/quickassetsmarket.com\/index.php\/2025\/12\/01\/wockhardt-jump-13-as-us-fda-accepts-nda-for-zaynich-antibiotic-in-key-milestone-for-indian-pharma\/"},"modified":"2025-12-01T11:35:07","modified_gmt":"2025-12-01T11:35:07","slug":"wockhardt-jump-13-as-us-fda-accepts-nda-for-zaynich-antibiotic-in-key-milestone-for-indian-pharma","status":"publish","type":"post","link":"https:\/\/quickassetsmarket.com\/index.php\/2025\/12\/01\/wockhardt-jump-13-as-us-fda-accepts-nda-for-zaynich-antibiotic-in-key-milestone-for-indian-pharma\/","title":{"rendered":"Wockhardt jump 13% as US FDA accepts NDA for Zaynich antibiotic in key milestone for Indian pharma"},"content":{"rendered":"
<\/div>\n

Shares of Indian pharmaceutical major Wockhardt rallied more than 13% on Monday after it announced a milestone development in its innovation pipeline: the United States Food and Drug Administration has formally accepted its New Drug Application for Zaynich, a novel antibiotic designed to target complicated urinary tract infections caused by multi-drug resistant gram-negative bacteria. <\/p>\n

The stock touched Rs 1,384 apiece on Monday, snapping a two-session losing streak and signaling renewed investor confidence around the company\u2019s research-led drug portfolio.<\/p>\n

A transformative regulatory landmark<\/h2>\n

In its exchange filing, Wockhardt described the NDA acceptance as a \u201ctransformative moment, not only for Wockhardt, but also for the entire Indian pharmaceutical industry.\u201d <\/p>\n

The drug application was first submitted on September 30.<\/p>\n

\u201cThis is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA,\u201d it added.<\/p>\n

The FDA has also granted fast-track designation to Zaynich, reflecting its potential to address urgent unmet clinical needs in patients suffering from infections where standard treatment options have failed.<\/p>\n

The priority review classification is expected to expedite regulatory timelines, bringing the drug closer to potential approval and commercial launch. <\/p>\n

Wockhardt said the recognition underscores confidence in its scientific approach and could open a pathway for more research-origin products from Indian companies to enter global markets.<\/p>\n

A decade-long research effort<\/h2>\n

The development of Zaynich began in 2011, driven by a program focused on anti-infective therapies for high-risk hospital-acquired infections. <\/p>\n

The company said the candidate works through a novel beta-lactam enhancer mechanism that has drawn international interest due to its strong efficacy against highly resistant gram-negative pathogens, organisms responsible for extended hospital stays and high mortality across regions. <\/p>\n

Compassionate-use cases in India and the US have already demonstrated clinical benefit in critically ill patients, according to the company.<\/p>\n

Wockhardt said this step reinforces its mission to advance next-generation anti-infective therapies amid growing global concern around antimicrobial resistance. <\/p>\n

\u201cThe FDA\u2019s acceptance of the Zaynich NDA is a historic and proud moment for the organization and for India. It reaffirms our commitment to developing advanced anti-infective solutions for the world and demonstrates what Indian science and innovation can achieve on the global stage,” Workhardt said. <\/p>\n

Commercial prospects and financial positioning<\/h2>\n

With more than 8 million cUTI cases reported annually across the US and EU, Wockhardt estimates the target market for gram-negative infections at over $7 billion. <\/p>\n

It plans to independently commercialise Zaynich in the US, while keeping strategic partnerships open. <\/p>\n

A successful launch could meaningfully expand its international footprint and strengthen revenue visibility, particularly in the European markets where it already has a strong presence.<\/p>\n

The company currently trades at an RSI level of 54, indicating neutral sentiment. <\/p>\n

In the second quarter ended September 2025, it reported a consolidated profit after tax of Rs 82 crore, reversing a Rs 16 crore loss in the same period last year. <\/p>\n

India revenue rose 3% to Rs 172 crore, while UK revenue grew 4% to Rs 313 crore.<\/p>\n

The NDA acceptance represents an unprecedented moment for Indian pharmaceutical R&D, placing Wockhardt at the centre of global attention as regulators evaluate what could become one of the first blockbuster anti-infectives developed from India for the world.<\/p>\n

The post Wockhardt jump 13% as US FDA accepts NDA for Zaynich antibiotic in key milestone for Indian pharma<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shares of Indian pharmaceutical major Wockhardt rallied more than 13% on Monday after it announced a milestone development in its innovation pipeline: the United States Food and Drug Administration has formally accepted its New Drug Application for Zaynich, a novel antibiotic designed to target complicated urinary tract infections caused by multi-drug resistant gram-negative bacteria. The <\/p>\n","protected":false},"author":1,"featured_media":45649,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":{"0":"post-45648","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"_links":{"self":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/45648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/comments?post=45648"}],"version-history":[{"count":0,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/45648\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media\/45649"}],"wp:attachment":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media?parent=45648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/categories?post=45648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/tags?post=45648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}